Zynerba Pharmaceuticals Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $23.48 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Zynerba Pharmaceuticals Inc had its IPO on 2015-08-05 under the ticker symbol ZYNE.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Zynerba Pharmaceuticals Inc has a staff strength of 0 employees.
Shares of Zynerba Pharmaceuticals Inc opened at $0.43 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $0.41 - $0.44, and closed at $0.42.
This is a -4.23% slip from the previous day's closing price.
A total volume of 59,198 shares were traded at the close of the day’s session.
In the last one week, shares of Zynerba Pharmaceuticals Inc have slipped by -10.34%.
Zynerba Pharmaceuticals Inc's Key Ratios
Zynerba Pharmaceuticals Inc has a market cap of $23.48 million, indicating a price to book ratio of 0.5356 and a price to sales ratio of 1152.6944.
In the last 12-months Zynerba Pharmaceuticals Inc’s revenue was $86000 with a gross profit of $0 and an EBITDA of $-35174184. The EBITDA ratio measures Zynerba Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Zynerba Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -29.04% with a return of equity of -54.53%.
In Q3, Zynerba Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Zynerba Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.89 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Zynerba Pharmaceuticals Inc’s profitability.
Zynerba Pharmaceuticals Inc stock is trading at a EV to sales ratio of 397.6066 and a EV to EBITDA ratio of 0.7757. Its price to sales ratio in the trailing 12-months stood at 1152.6944.
Zynerba Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $62.37 million
- Total Liabilities
- $9.43 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Zynerba Pharmaceuticals Inc ended 2023 with $62.37 million in total assets and $0 in total liabilities. Its intangible assets were valued at $62.37 million while shareholder equity stood at $52.76 million.
Zynerba Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $9.43 million in other current liabilities, 47063.00 in common stock, $-266501253.00 in retained earnings and $0 in goodwill. Its cash balance stood at $55.93 million and cash and short-term investments were $55.93 million. The company’s total short-term debt was $213,428 while long-term debt stood at $0.
Zynerba Pharmaceuticals Inc’s total current assets stands at $60.80 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.38 million compared to accounts payable of $1.62 million and inventory worth $0.
In 2023, Zynerba Pharmaceuticals Inc's operating cash flow was $-95098.00 while its capital expenditure stood at $95098.
Comparatively, Zynerba Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Zynerba Pharmaceuticals Inc stock is currently trading at $0.42 per share. It touched a 52-week high of $2.105 and a 52-week low of $2.105. Analysts tracking the stock have a 12-month average target price of $5.44.
Its 50-day moving average was $0.52 and 200-day moving average was $0.79 The short ratio stood at 0.92 indicating a short percent outstanding of 0%.
Around 462.1% of the company’s stock are held by insiders while 1500.4% are held by institutions.
Frequently Asked Questions About Zynerba Pharmaceuticals Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.